Extensive Product Profile: Understanding Obesema 0.25 mg Obesema 0.25 mg Injection is an advanced therapeutic agent containing semaglutide, a potent GLP-1 (Glucagon-Like Peptide-1) receptor agonist. This 0.25 mg strength is specifically formulated as the initiation dose. It is designed to introduce the medication to the body’s metabolic system over a 4-week period, minimizing gastrointestinal sensitivity and preparing the patient for subsequent maintenance doses. 1. Clinical Indications & Usage Chronic Weight Management: Indicated for long-term weight reduction in adults with obesity (BMI ≥ 30 kg/m who have weight-related comorbidities such as hypertension, dyslipidemia, or type 2 diabetes. Glycemic Control: Used as an adjunct to diet and exercise to improve blood sugar levels in adults with Type 2 Diabetes Mellitus. Cardiovascular Protection: Proven to reduce the risk of major adverse cardiovascular events (MACE), including heart attack and stroke, in adults with established heart disease and elevated BMI. Adolescent Obesity: Approved for weight management in pediatric patients aged 12 years and older who meet defined obesity thresholds. 2. Mechanism of Action: The Science of Metabolic Signaling Obesema works by mimicking the natural incretin hormone GLP-1, which is released by the intestines after eating. Its primary mechanisms include: Satiety Induction: It targets receptors in the brain that signal fullness, effectively reducing appetite and suppressing intense food cravings. Delayed Gastric Emptying: It slows down the rate at which food leaves the stomach, leading to a more gradual absorption of glucose and a prolonged feeling of satiety. Glucose-Dependent Insulin Secretion: It stimulates the pancreas to release insulin only when blood sugar is high, preventing hyperglycemia without the high risk of hypoglycemia. Glucagon Suppression: It inhibits the secretion of glucagon, preventing the liver from releasing stored sugar unnecessarily. 3. Administration and Dosing Route: Subcutaneous injection in the abdomen, thigh, or upper arm. Frequency: Administered once weekly on the same day each week. Pen Presentation: Typically provided in a multi-dose disposable pen with accompanying sterile needles and alcohol swabs for ease of use. Storage, Handling, and Stability Protocols Maintaining the molecular integrity of the Semaglutide peptide is critical for therapeutic efficacy: Primary Cold-Chain: Store unused pens in a refrigerator between 2°C and 8°C. In-Use Stability: Once the pen is first used, it can be kept at room temperature (below 30°C) or in the refrigerator for up to 56 days. Light Protection: Always keep the pen cap on when not in use to protect the solution from light exposure. Crucial Safety: Do not freeze. Freezing denatures the peptide structure. If the solution becomes frozen, it must be discarded immediately. Why Partner with Ernest Impex for Global Sourcing? GMP Certified Supply: We source directly from top Indian manufacturers like Alkem Laboratories Ltd. to ensure 100% genuine products. Advanced Cold-Chain Logistics: Specialized temperature-controlled shipping to ensure product stability during transit to the USA, UK, Southeast Asia, and the Caribbean. Full Documentation Suite: We provide Certificates of Analysis (COA), Commercial Invoices, and regulatory paperwork for TGA, HSA, US-FDA, and MHRA compliance. PRESCRIPTION MEDICINE IS YES The information provided is for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any medical or treatment decisions. 📞 Contact Ernest Impex — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.ernestimpex.com www.ernestvision.com www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 📲 WhatsApp Link: https://wa.me/919359902383